Table 1.
Accrual to whole brain radiotherapy trials
| Trial | Design | Histology and no. of BMs | Appropriate NCF testing | Actual recruitment (patients/years) | Average no. of patients accrued per year | Total number of melanoma patients (%) |
|---|---|---|---|---|---|---|
| Patchell et al. [8] |
WBRT vs. OBS |
All solid tumours (mainly lung) Sol BM post- surgery |
No |
96/8 years |
12 |
2 (2%) |
| Aoyama et al. [9] |
SR vs. WBRT + SRS |
All solid tumours (mainly lung) 1–4 BMs |
No |
132/4 years |
33 |
Unknown |
| Kocher et al. [10] |
SR vs. SR + WBRT |
All solid tumours (mainly lung) 1–3 BMs |
No |
359/11 years |
33 |
18 (5%) |
| Chang et al. [11] |
SR vs. WBRT + SR |
All solid tumours (mainly lung) 1–3 BMs |
Yes |
58/6 years |
10 Early closure |
7 patients (12%) |
| Roos et al. [12]* |
WBRT vs. OBS |
All solid tumours sol BM post-SR/surgery |
No |
19/3 years |
6 |
3 (16%) |
| This study | WBRT vs. observation | Melanoma only 1–3 BMs post-SR/surgery | Yes | 54/2 years | 27 | 54 (100%) |
WBRT - Whole Brain Radiotherapy.
SR - Stereotactic Radiosurgery.
Sol BM - solitary Brain Metastases.
OBS- observation.
NCF - Neurocognitive.
*Early closure due to poor accrual.